Cwm LLC Has $3.02 Million Stake in IDEXX Laboratories, Inc. $IDXX

Cwm LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.2% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,637 shares of the company’s stock after selling 438 shares during the period. Cwm LLC’s holdings in IDEXX Laboratories were worth $3,023,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC boosted its stake in IDEXX Laboratories by 6.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 14,190 shares of the company’s stock valued at $7,612,000 after purchasing an additional 848 shares during the last quarter. Sovereign Financial Group Inc. purchased a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $214,000. Concurrent Investment Advisors LLC boosted its stake in shares of IDEXX Laboratories by 8.7% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,489 shares of the company’s stock worth $799,000 after buying an additional 119 shares during the last quarter. Manitou Investment Management Ltd. boosted its stake in shares of IDEXX Laboratories by 69.7% in the 2nd quarter. Manitou Investment Management Ltd. now owns 95,487 shares of the company’s stock worth $51,213,000 after buying an additional 39,233 shares during the last quarter. Finally, Conning Inc. purchased a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $213,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research note on Monday, August 4th. BTIG Research boosted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $656.50.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,200 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the sale, the executive vice president owned 16,807 shares in the company, valued at $11,034,299.71. This represents a 6.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 2,187 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the sale, the director owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $635.40 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The business’s 50 day simple moving average is $639.99 and its 200 day simple moving average is $549.35. The company has a market cap of $50.84 billion, a price-to-earnings ratio of 52.91, a PEG ratio of 4.13 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business earned $2.44 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.